Search Results
Jun 02, 2026, 03:23 ET Ping An Launches "Ping An Home" Service Brand
An Home" transforms the concept of healthy longevity into practical, family‑oriented health services embedded in daily life, extending insurance from post‑event risk compensation to full‑lifecycle health support.In parallel, PKU Healthcare Group, a Ping An subsidiary, recently partnered with Fudan
More news about: Ping An Insurance (Group) Company of China, Ltd.
Jun 02, 2026, 03:00 ET Yozma tillkännager Landmark Football Partnership inför sitt ettårsjubileum
YozmasportMediekontaktFöretag: YozmasportsKontakt: ZachE-post: [email protected] Webbplats:
More news about: Yozmasports
Jun 02, 2026, 02:52 ET Ping An Launches "Ping An Home" Service Brand
An Home" transforms the concept of healthy longevity into practical, family‑oriented health services embedded in daily life, extending insurance from post‑event risk compensation to full‑lifecycle health support.In parallel, PKU Healthcare Group, a Ping An subsidiary, recently partnered with Fudan
More news about: Ping An Insurance (Group) Company of China, Ltd.
Jun 02, 2026, 00:54 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
rapid and efficient hematopoietic reconstitution, with neutrophil engraftment observed on Day 13 and platelet counts exceeding 50×10^9/L on Day 21 post-treatment. Within one month after treatment, fetal hemoglobin (HbF) levels increased significantly and continuously, while sickle hemoglobin (HbS) levels
More news about: CorrectSequence Therapeutics
Jun 02, 2026, 00:50 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
rapid and efficient hematopoietic reconstitution, with neutrophil engraftment observed on Day 13 and platelet counts exceeding 50×10^9/L on Day 21 post-treatment. Within one month after treatment, fetal hemoglobin (HbF) levels increased significantly and continuously, while sickle hemoglobin (HbS) levels
More news about: CorrectSequence Therapeutics
Jun 01, 2026, 23:38 ET Dnotitia Releases DNA 3.0, an Enterprise-Ready AI Language Model Family
institutional and enterprise useDnotitia releases DNA 3.0, a family of AI language models built on Qwen 3.5/3.6 and enhanced through proprietary post-trainingThe model family is designed to help organizations adapt AI to their own data, workflows, and response policiesDNA models
More news about: Dnotitia Inc.
Jun 01, 2026, 16:33 ET Bill Lockyer, Ex-CA Attorney General: Paramount-Warner Bros. Should Be Reviewed -- Not Automatically Resisted
global competitive advantages, and a source of well-paying jobs for hundreds of thousands of Californians. From soundstages in Los Angeles to post-production facilities, visual effects shops, small vendors, independent contractors and family-owned businesses across the state, the movie and television
More news about: Bill Lockyer
Jun 01, 2026, 16:05 ET WF International Limited Announces Share Consolidation
consolidation of its ordinary shares on a ten-to-one basis (the "Share Consolidation"). The Company's ordinary shares will begin trading on a post consolidation basis on June 4, 2026. As a result of the Share Consolidation, each ten (10) pre-consolidation ordinary shares of the Company will
More news about: WF International Limited
Jun 01, 2026, 16:04 ET /C O R R E C T I O N -- Schlesinger Law Offices, P.A./
was returned on May 29, 2026, in the Circuit Court of the Twentieth Judicial Circuit in and for Charlotte County, Florida. The case remains subject to post-trial motions and appellate review.About Schlesinger Law OfficesSchlesinger Law Offices represents individuals and families throughout
More news about: Schlesinger Law Offices, P.A.
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
interruption and/or dose modification in 2.1% of patients and to discontinuation of IMDYLLTRA in 0.6% of patients. Fatal CRS cases have been reported in the post-marketing setting.CRS may be associated with symptoms including pyrexia, hypotension, hypoxia, fatigue, tachycardia, headache, chills,
More news about: Amgen
Jun 01, 2026, 13:13 ET How a Digital Agency Transformed a Complex B2B Catalogue Into a Scalable Website
greater attention from the outset, with teams integrating cookie management and analytics configurations as core components of new site builds rather than post-launch additions.About Digital SilkDigital Silk is an award-winning Miami
More news about: Digital Silk
Jun 01, 2026, 11:48 ET Boar's Head® Introduces Pickle Snacks: A Premium Take on the Growing Pickle Craze
flavors, and are Certified Kosher. Boar's Head Pickle Snacks are designed to fit seamlessly into modern lifestyles - from busy afternoons to post-workout refueling or travel-friendly moments. To learn more about the Boar's Head Pickle Snacks Collection and where to find it, visit
More news about: Boar's Head
Jun 01, 2026, 11:42 ET JA Solar domine le marché du photovoltaïque post-cycle grâce à des percées en matière de solutions à double technologie et intégrées
1er juin 2026 /PRNewswire/ -- JA Solar a récemment présenté ses axes stratégiques pour le marché photovoltaïque (PV) post-cycle, réaffirmant son leadership dans les technologies TOPCon et BC tout en progressant vers un modèle de solutions énergétiques entièrement intégrées.
More news about: JA Solar Technology Co., Ltd.
Jun 01, 2026, 11:26 ET SignalPlus Closes B1 Round at US$500M Valuation to Accelerate Global Expansion and Advance Derivatives Trading Technology
institutional digital assets options and derivatives trading infrastructure, today announced the closing of its US$50M Series B1 funding round at a post-money valuation of US$500M. This round was led by HashKey Capital, with follow-on participation from BlockBooster and AppWorks. This investment reflects
More news about: SignalPlus
Jun 01, 2026, 11:00 ET Relativity Launches Relativity FOIA to Streamline Public Disclosure Operations for Government Agencies
detailed blog post about the solution, or join Relativity at 10:00 a.m. CT on June 23 for an
More news about: Relativity
Jun 01, 2026, 11:00 ET Relativity Launches Relativity FOIA to Streamline Public Disclosure Operations for Government Agencies
detailed blog post about the solution, or join Relativity at 10:00 a.m. CT on June 23 for an
More news about: Relativity
Jun 01, 2026, 11:00 ET 5W AI Communications Releases the IPO AI Visibility Index: The Companies Going Public Are Losing the First Question Buyers Ask
than the market did.— Famous and defenseless. Klarna and Figma are recognized perfectly and explained largely through the post-IPO decline narrative the press authored. None of it is factually wrong. Much of it is uncontrolled. This is the most expensive failure mode in the
More news about: 5W Public Relations
Jun 01, 2026, 10:34 ET JA Solar ist dank bahnbrechender Dual-Technologie-Entwicklungen und integrierter Lösungen führend auf dem Post-Cycle-PV-Markt
BEIJING, 1. Juni 2026 /PRNewswire/ -- JA Solar hat kürzlich seine strategische Roadmap für den Post-Zyklus-Photovoltaikmarkt (PV) vorgestellt und dabei seine Führungsposition bei den TOPCon- und BC-Technologien bekräftigt, während das Unternehmen gleichzeitig
More news about: JA Solar Technology Co., Ltd.
Jun 01, 2026, 09:40 ET Escape into Endless Summer with dōTERRA's New Seasonal Collection
Endless Summer Hair & Body Mist transforms the beloved scent into a refreshing personal care experience. Designed for warm-weather moments – from post-beach afternoons to everyday on-the-go refreshes – the mist delivers a light, effortless fragrance for both hair and skin.Highlights include:
More news about: doTERRA International, LLC
Jun 01, 2026, 09:24 ET Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
Objective response rate (ORR) was 35.6%, including one complete response.Disease control rate was 82.2%.Further, a post-hoc analysis was conducted in a more clearly defined aggressive ACC subtype reflecting clinical features used in practice by clinicians and pathologists,
More news about: Servier Pharmaceuticals
Jun 01, 2026, 09:11 ET Technosylva Unveils Groundbreaking Utility Storm Preparedness and Restoration Capabilities on Expanded Extreme Weather Risk Intelligence Platform
operations. This enables electric utilities to anticipate, scope, and prepare for extreme weather events up to 5 days before they arrive, and manage the post-event restoration efforts. As part of its comprehensive grid-reliance initiative, Houston-based CenterPoint Energy has deployed the system, which was
More news about: Technosylva
Jun 01, 2026, 09:10 ET Whirlpool Announces Tender Offer and Consent Solicitation for Outstanding Notes Due 2026 and 2027
technology research centers. Additional information about the company can be found at WhirlpoolCorp.com.WEBSITE DISCLOSUREWe routinely post important information for investors on our website, WhirlpoolCorp.com, in the "Investors" section. We also intend to update the "Hot Topics Q&A"
More news about: Whirlpool Corporation
Jun 01, 2026, 09:08 ET Whirlpool Announces Offering of Secured Notes
which were in the Americas—41,000 employees and 35 manufacturing and technology research centers.WEBSITE DISCLOSUREWe routinely post important information for investors on our website, WhirlpoolCorp.com, in the "Investors" section. We also intend to update the "Hot Topics Q&A"
More news about: Whirlpool Corporation
Jun 01, 2026, 09:00 ET Revance Supports Acne Awareness Month with SkinPen and PanOxyl Partnership Campaign
The brands unite to support consumers through every stage of the acne journey, from active breakouts to the appearance of post-acne scarringNASHVILLE, Tenn., June 1, 2026 /PRNewswire/ -- This Acne
More news about: Revance
Jun 01, 2026, 09:00 ET Paradigm Health Implements New Clinical Trial Solution to Support Observational Study Presented at ASCO
June 1, 2026 /PRNewswire/ -- Paradigm Health today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in the United States evaluating an FDA-approved therapy in patients with human epidermal growth factor receptor 2 (HER2)
More news about: Paradigm Health, Inc.